Impact of MYD88
Adult
Aged
Aged, 80 and over
Amino Acid Substitution
Cell Transformation, Neoplastic
/ genetics
Disease-Free Survival
Female
Follow-Up Studies
Humans
Lymphoma
/ genetics
Male
Middle Aged
Mutation, Missense
Myeloid Differentiation Factor 88
/ genetics
Neoplasm Proteins
/ genetics
Survival Rate
Time Factors
Waldenstrom Macroglobulinemia
/ genetics
Journal
American journal of hematology
ISSN: 1096-8652
Titre abrégé: Am J Hematol
Pays: United States
ID NLM: 7610369
Informations de publication
Date de publication:
03 2020
03 2020
Historique:
received:
23
11
2019
revised:
01
12
2019
accepted:
04
12
2019
pubmed:
10
12
2019
medline:
19
5
2020
entrez:
10
12
2019
Statut:
ppublish
Résumé
Histological transformation in Waldenström macroglobulinemia (WM) is an uncommon complication, with limited data, particularly regarding the impact of MYD88
Substances chimiques
MYD88 protein, human
0
Myeloid Differentiation Factor 88
0
Neoplasm Proteins
0
Types de publication
Clinical Trial
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
274-281Informations de copyright
© 2019 Wiley Periodicals, Inc.
Références
Kapoor P, Ansell SM, Fonseca R, et al. Diagnosis and management of waldenstrom macroglobulinemia: mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines 2016. JAMA Oncol. 2017;3(9):1257-1265.
Owen RG, Bynoe AG, Varghese A, de Tute RM, Rawstron AC. Heterogeneity of histological transformation events in waldenstrom's macroglobulinemia (WM) and related disorders. Clin Lymphoma Myeloma Leuk. 2011;11(1):176-179.
Garcia-Sanz R, Montoto S, Torrequebrada A, et al. Waldenstrom macroglobulinaemia: presenting features and outcome in a series with 217 cases. Br J Haematol. 2001;115(3):575-582.
Kyle RA, Treon SP, Alexanian R, et al. Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the second international workshop on waldenstrom's macroglobulinemia. Semin Oncol. 2003;30(2):116-120.
Bustoros M, Sklavenitis-Pistofidis R, Kapoor P, et al. Progression risk stratification of asymptomatic waldenstrom macroglobulinemia. J Clin Oncol. 2019;37(16):1403-1411.
Abeykoon JP, Zanwar S, Ansell SM, et al. Predictors of symptomatic hyperviscosity in Waldenström macroglobulinemia. Am J Hematol. 2018;93(11):1384-1393.
Casulo C, Burack WR, Friedberg JW. Transformed follicular non-Hodgkin lymphoma. Blood. 2015;125(1):40-47.
Parikh SA, Habermann TM, Chaffee KG, et al. Hodgkin transformation of chronic lymphocytic leukemia: Incidence, outcomes, and comparison to de novo Hodgkin lymphoma. Am J Hematol. 2015;90(4):334-338.
Hunter ZR, Xu L, Yang G, et al. The genomic landscape of waldenström macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis. Blood. 2014;123(11):1637-1646.
Abeykoon JP, Paludo J, King RL, et al. MYD88 mutation status does not impact overall survival in waldenstrom macroglobulinemia. Am J Hematol. 2018;93(2):187-194.
Jimenez C, Sebastian E, Chillon MC, et al. MYD88 L265P is a marker highly characteristic of, but not restricted to waldenstrom's macroglobulinemia. Leukemia. 2013;27(8):1722-1728.
Ngo VN, Young RM, Schmitz R, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature. 2011;470(7332):115-119.
Schmitz R, Wright GW, Huang DW, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med. 2018;378(15):1396-1407.
Ansell SM, Hodge LS, Secreto FJ, et al. Activation of TAK1 by MYD88 L265P drives malignant B-cell growth in non-Hodgkin lymphoma. Blood Cancer J. 2014;4:e183.
Wenzl K, Manske MK, Sarangi V, et al. Loss of TNFAIP3 enhances MYD88L265P-driven signaling in non-Hodgkin lymphoma. Blood Cancer J. 2018;8(10):97.
Link BK, Maurer MJ, Nowakowski GS, et al. Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/mayoclinic specialized program of research excellence molecular epidemiology Resource. J Clin Oncol. 2013;31(26):3272-3278.
Rossi D, Cerri M, Capello D, et al. Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndrome. Br J Haematol. 2008;142(2):202-215.
Kapoor P, Ansell SM, Fonseca R, et al. Diagnosis and management of waldenström macroglobulinemia: mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines 2016. JAMA Oncol. 2017;3(9):1257-1265.
Armitage JO. Staging non-Hodgkin lymphoma. CA Cancer J Clin. 2005;55(6):368-376.
Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579-586.
Xu L, Hunter ZR, Yang G, et al. MYD88 L265P in waldenstrom macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. Blood. 2013;121(11):2051-2058.
Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275-282.
Al-Tourah AJ, Gill KK, Chhanabhai M, et al. Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma. J Clin Oncol. 2008;26(32):5165-5169.
Montoto S, Davies AJ, Matthews J, et al. Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. J Clin Oncol. 2007;25(17):2426-2433.
Castillo JJ, Gustine J, Meid K, Dubeau T, Hunter ZR, Treon SP. Histological transformation to diffuse large B-cell lymphoma in patients with Waldenstrom macroglobulinemia. Am J Hematol. 2016;91(10):1032-1035.
Durot E, Tomowiak C, Michallet AS, et al. Transformed waldenstrom macroglobulinaemia: clinical presentation and outcome. A multi-institutional retrospective study of 77 cases from the French Innovative Leukemia Organization (FILO). Br J Haematol. 2017;179(3):439-448.
Sehn LH, Berry B, Chhanabhai M, et al. The revised International prognostic index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109(5):1857-1861.
Dalia S, Bello CM, Sokol L, Sotomayor EM, Shah BD, Chavez JC. The revised International prognostic Index (R-IPI) score is predictive of survival in aggressive transformed lymphomas (TL) from low grade non-Hodgkin lymphomas in the chemoimmunotherapy Era. Blood. 2013;122(21):4275-4275.
Treon SP, Gustine J, Xu L, et al. MYD88 wild-type waldenstrom macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survival. Br J Haematol. 2018;180(3):374-380.
Guerrera ML, Tsakmaklis N, Xu L, et al. MYD88 mutated and wild-type waldenstrom's macroglobulinemia: characterization of chromosome 6q gene losses and their mutual exclusivity with mutations in CXCR4. Haematologica. 2018;103(9):e408-e411.
Hunter ZR, Xu L, Tsakmaklis N, et al. Insights into the genomic landscape of MYD88 wild-type Waldenstrom macroglobulinemia. Blood Adv. 2018;2(21):2937-2946.
Abeykoon JP, King R, Ansell SM, et al. Reply to Castillo et al. Am J Hematol. 2018;93(3):E71-E73.